Kidney cancer, Renal cell cancer, Secondary cancers
Results
Phase 2
This trial looked at everolimus for papillary renal cell cancer that had spread to another part of the body. Everolimus is also called RAD001 and Afinitor.
The trial was open for people to join between 2009 and 2011. The team published the results in 2016. There is a link to more information in the ‘Summary of results’ section below.
Recruitment start: 1 July 2009
Recruitment end: 4 August 2011
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Paul Nathan
Experimental Cancer Medicine Centre (ECMC)
Novartis
Last reviewed: 7 November 2023
CRUK internal database number: 5858
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
